Stem cell therapy for diabetes and related conditions Market expected to reach $510 billion a year by 2030
In 2015, the American Diabetes Association (ADA) estimated that the annual total cost of diabetic patients is $223.5 billion in the US alone. The global annual cost is estimated at $465 billion and is expected to reach $510 billion a year by 2030.
In 2015, the American Diabetes Association (ADA) estimated that the annual total cost of diabetic patients is $223.5 billion in the US alone. The global annual cost is estimated at $465 billion and is expected to reach $510 billion a year by 2030.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Stem</strong> Cell Therapy <strong>for</strong> Diabetes <strong>and</strong> Related<br />
Conditions Is Expected To Reach <strong>$510</strong> Billion<br />
A Year By <strong>2030</strong><br />
“In 2015, the American Diabetes Association (ADA)<br />
estimated that the annual <strong>to</strong>tal cost of diabetic<br />
patients is $223.5 <strong>billion</strong> in the US alone. The global<br />
annual cost is estimated at $465 <strong>billion</strong> <strong>and</strong> is<br />
<strong>expected</strong> <strong>to</strong> <strong>reach</strong> <strong>$510</strong> <strong>billion</strong> a <strong>year</strong> <strong>by</strong> <strong>2030</strong>.”<br />
The stem <strong>cell</strong> <strong>therapy</strong> <strong>for</strong> <strong>diabetes</strong> <strong>and</strong> <strong>related</strong> <strong>conditions</strong> pipeline analysis report<br />
includes ongoing clinical <strong>and</strong> non-clinical trends in the global stem <strong>cell</strong> <strong>therapy</strong> <strong>for</strong><br />
<strong>diabetes</strong> <strong>and</strong> <strong>related</strong> <strong>conditions</strong> treatment. Most of the pipeline therapeutics are in early<br />
stage of development, a long-lasting <strong>and</strong> less frequent dose can impact overall <strong>diabetes</strong><br />
market.<br />
In 2015, the American Diabetes Association (ADA) estimated that the annual <strong>to</strong>tal cost<br />
of diabetic patients is $223.5 <strong>billion</strong> in the US alone. The global annual cost is estimated<br />
at $465 <strong>billion</strong> <strong>and</strong> is <strong>expected</strong> <strong>to</strong> <strong>reach</strong> <strong>$510</strong> <strong>billion</strong> a <strong>year</strong> <strong>by</strong> <strong>2030</strong>.<br />
The report covers the present scenario <strong>and</strong> the growth prospects of the stem <strong>cell</strong><br />
<strong>therapy</strong> <strong>for</strong> <strong>diabetes</strong> <strong>and</strong> <strong>related</strong> <strong>conditions</strong>. The report presents a detailed picture of the<br />
market <strong>by</strong> way of study, synthesis, <strong>and</strong> summation of data from multiple sources.<br />
Request A Sample Copy Of This Report:<br />
https://www.radiantinsights.com/research/stem-<strong>cell</strong>-<strong>therapy</strong>-<strong>for</strong>-<strong>diabetes</strong><strong>and</strong>-<strong>related</strong>-<strong>conditions</strong>-a-pipeline-analysis-report/request-sample<br />
Follow Us:
Key questions answered in this report<br />
• How will the market evolve during the <strong>for</strong>ecast period?<br />
• What are the major parameters impacting the market?<br />
• What are the key market trends?<br />
• What are the challenges <strong>to</strong> market growth?<br />
• Who are the key companies in this market space?<br />
The report covers the present scenario <strong>and</strong> the growth prospects of the stem <strong>cell</strong><br />
<strong>therapy</strong> <strong>for</strong> <strong>diabetes</strong> <strong>and</strong> <strong>related</strong> <strong>conditions</strong>. The report presents a detailed picture of the<br />
market <strong>by</strong> way of study, synthesis, <strong>and</strong> summation of data from multiple sources.<br />
Radiant Insights <strong>Stem</strong> Cell Therapy <strong>for</strong> Diabetes <strong>and</strong> Related Conditions - A Pipeline<br />
Analysis Report, has been prepared based on an in-depth market analysis with inputs<br />
from industry experts. The report covers the market l<strong>and</strong>scape <strong>and</strong> its growth prospects<br />
during the <strong>for</strong>ecast period. The report also includes a discussion of the key companies<br />
operating in this market.<br />
Major companies<br />
• Athersys<br />
• Mesoblast<br />
• Caladrius Biosciences<br />
• Sanofi<br />
• Novo Nordisk<br />
Browse Full Research Report:<br />
https://www.radiantinsights.com/research/stem-<strong>cell</strong>-<strong>therapy</strong>-<strong>for</strong>-<strong>diabetes</strong><strong>and</strong>-<strong>related</strong>-<strong>conditions</strong>-a-pipeline-analysis-report<br />
Table of Contents:<br />
PART 01: Executive summary<br />
PART 02: Scope of the report<br />
PART 03: Research Methodology<br />
PART 04: Introduction<br />
• <strong>Market</strong> outline<br />
PART 05: <strong>Market</strong> l<strong>and</strong>scape<br />
• <strong>Market</strong> overview<br />
• Five <strong>for</strong>ces analysis<br />
PART 06: Pipeline l<strong>and</strong>scape<br />
PART 07: <strong>Market</strong> segmentation <strong>by</strong> <strong>therapy</strong><br />
• Immunoglobulin <strong>therapy</strong><br />
• Antibiotics<br />
• Others<br />
PART 08: Geographical segmentation<br />
Follow Us:
• PIDDs treatment market in Americas<br />
• PIDDs treatment market in EMEA<br />
• PIDDs treatment market in APAC<br />
PART 09: Decision framework<br />
PART 10: Drivers <strong>and</strong> challenges<br />
• <strong>Market</strong> drivers<br />
List of Exhibits<br />
• Exhibit 01: Features of PIDDs<br />
• Exhibit 02: Signs <strong>and</strong> symp<strong>to</strong>ms of PI<br />
• Exhibit 03: PIDDs classification based on affected immune system<br />
• Exhibit 04: Diagnosis <strong>and</strong> treatment of PI<br />
• Exhibit 05: Global PIDDs treatment market 2016-2021 ($ millions)<br />
• Exhibit 06: Opportunity analysis of global PIDDs treatment market<br />
• Exhibit 07: Five <strong>for</strong>ces analysis<br />
• Exhibit 08: Pipeline analysis of vendors in global PIDDs treatment market<br />
• Exhibit 09: Key clinical trials<br />
• Exhibit 10: <strong>Market</strong> segmentation <strong>by</strong> <strong>therapy</strong><br />
• Exhibit 11: Global PIDDs treatment market <strong>by</strong> immunoglobulin <strong>therapy</strong> 2016-2021 ($<br />
millions)<br />
• Exhibit 12: Global PIDDs treatment market <strong>by</strong> antibiotics 2016-2021 ($ millions)<br />
• Exhibit 13: Antibiotic prophylaxis regimens in several PIDDs<br />
• Exhibit 14: Global PIDDs treatment market <strong>by</strong> others 2016-2021 ($ millions)<br />
• Exhibit 15: Segmentation of global PIDDs treatment market <strong>by</strong> geography 2016 <strong>and</strong><br />
2021<br />
• Exhibit 16: Global PIDDs treatment market revenue <strong>by</strong> geography 2016-2021 ($<br />
millions)<br />
• Exhibit 17: <strong>Market</strong> scenario in Americas<br />
• Exhibit 18: PIDDs treatment market in Americas 2016-2021 ($ millions)<br />
• Exhibit 19: <strong>Market</strong> scenario in EMEA<br />
• Exhibit 20: PIDDs treatment market in EMEA 2016-2021 ($ millions)<br />
• Exhibit 21: <strong>Market</strong> scenario in APAC<br />
• Exhibit 22: PIDDs treatment market in APAC 2016-2021 ($ millions)<br />
• Exhibit 23: Fractionation capacities of key vendors<br />
• Exhibit 24: Various side effects associated with immunoglobulin <strong>therapy</strong><br />
• Exhibit 25: Fac<strong>to</strong>rs contributing <strong>to</strong> overall cost of production <strong>for</strong> IVIG<br />
• Exhibit 26: Detailed in<strong>for</strong>mation regarding processes required <strong>for</strong> TGA approval<br />
• Exhibit 27: Fractionating capacities globally in 2007 <strong>and</strong> 2012<br />
• Exhibit 28: Competitive structure analysis of global PIDDs treatment market 2016<br />
• Exhibit 29: Competitive fac<strong>to</strong>rs of global PIDDs treatment market<br />
See More Reports of This Category <strong>by</strong> Radiant Insights:<br />
https://www.radiantinsights.com/catalog/healthcare<br />
Follow Us:
About Radiant Insights, Inc:<br />
Radiant Insights is a plat<strong>for</strong>m <strong>for</strong> companies looking <strong>to</strong> meet their market<br />
research <strong>and</strong> business intelligence requirements. We assist <strong>and</strong> facilitate<br />
organizations <strong>and</strong> individuals procure market research reports, helping them in<br />
the decision making process. We have a comprehensive collection of reports,<br />
covering over 40 key industries <strong>and</strong> a host of micro markets. In addition <strong>to</strong> over<br />
extensive database of reports, our experienced research coordina<strong>to</strong>rs also offer<br />
a host of ancillary services such as, research partnerships/ tie-ups <strong>and</strong><br />
cus<strong>to</strong>mized research solutions.<br />
Contact Details:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
Radiant Insights, Inc.201 Spear St #1100, Suite #3036San Francisco, CA 94105<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Web: http://www.radiantinsights.com/<br />
Follow Us:
Change language